Lilly posts second-quarter loss on hefty Zyprexa settlement

"Eli Lilly & Co. posted a second-quarter loss Thursday after taking a one-time charge of $1.07 billion to cover a product liability case involving its top-selling drug, the anti-psychotic treatment Zyprexa." [Miami.com]